A phase II study of Docetaxel with Bevacizumab for previously treated non-squamous non-small cell lung cancer.
- Conditions
- non-squamous non-small cell lung cancer.
- Registration Number
- JPRN-UMIN000008687
- Lead Sponsor
- First Department of Internal Medicine,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1. Prior treatment with Docetaxel. 2. History or complication of hemoptysis with 2.5mL per time or more. 3.Patients with lesions at risk of causing hemoptysis in hilar by chest CT. 4. Invasion to major vessel of tumor. 5. Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 6.Have uncontrolled effusion (Pleural, peritoneal effusion, or cardiac effusion which requires drainage for symptom management). 7. Planning of concurrent thoracic radiotherapy (including if radiation field does not cover the chest). 8. Have active CNS metastases. 9. Have another active malignancy. 10. Major surgery within 4wks prior to the study. 11. Urinary protein <= 2+ 12. Patients with therapeutic anticoagulopathy. 13. Have a history of serious systemic disease. 14. In pregnancy, during breast feeding, or possibility of pregnancy. 15. With a history of serious drug sensitivity. 16. Mental disease or psychotic manifestation. 17. Severe infection such as having a HCV Ab positive or HbsAg positive. 18. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Response Rate Overall Survival Safety Profile